Holen Sie sich die Stockscreener-App
1.00
0.00%
0.00
Silexion Therapeutics Corp Aktie (SLXN) Neueste Nachrichten
Is Silexion Therapeutics Corp (SLXN) positioned for future growth? - Sete News
Silexion Therapeutics Partners with Catalent to Advance Revolutionary KRAS-Targeting Cancer Therapy - citybuzz -
Silexion Therapeutics partners with Catalent for cancer drug development By Investing.com - Investing.com South Africa
SLXN’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com
Silexion Partners With Catalent To Advance SIL204 SiRNA Therapy For KRAS-Driven Cancers - Nasdaq
Silexion Therapeutics Partners with Catalent for SIL204 Development - TipRanks
Silexion Therapeutics partners with Catalent for cancer drug development - Investing.com Australia
Silexion Therapeutics enters collaboration with Catalent - TipRanks
Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers - Nasdaq
Silexion Therapeutics Announces Collaboration with Global - GlobeNewswire
Major Breakthrough: Silexion's Multi-KRAS Cancer Drug Enters Manufacturing Phase with Industry Giant Catalent - Stock Titan
Titan Pharmaceuticals (NASDAQ:TTNP) and Silexion Therapeutics (NASDAQ:SLXN) Head to Head Review - Defense World
Silexion plans dual-route strategy for SIL-204 for KRAS-driven pancreatic cancer - BioWorld MedTech
Buy Rating for Silexion Therapeutics Driven by Promising SIL-204 Developments and Market Expansion - TipRanks
Silexion advances dual-route strategy for KRAS cancer therapy By Investing.com - Investing.com South Africa
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data - markets.businessinsider.com
Silexion Therapeutics Unveils Innovative Expanded - GlobeNewswire
Silexion Therapeutics announces expanded development plan for SIL204 - TipRanks
Silexion Therapeutics Expands SIL204 Development Plan - TipRanks
Silexion advances dual-route strategy for KRAS cancer therapy - Investing.com
Silexion Therapeutics Corp Unveils Expanded Development Plan For Sil204 - MarketScreener
Game-Changing Cancer Treatment: Silexion's New Dual-Action Drug Targets Both Primary Tumors and Metastases - Stock Titan
Maxim Group Cuts Silexion Therapeutics (NASDAQ:SLXN) Price Target to $5.00 - Defense World
Silexion Therapeutics price target lowered to $5 from $9 at Maxim - MSN
Silexion announces completion of expanded development plan for SIL204 - TipRanks
Silexion Therapeutics Corp. Announces Expanded Development Plan for SIL204 at NeauxCancer 2025 Conference - Nasdaq
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - GlobeNewswire
Revolutionary KRAS Cancer Treatment: Silexion Expands Development Strategy for SIL204 - StockTitan
Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Silexion Therapeutics Corp. Reports 2024 Financial Results and Progress on SIL204 for KRAS-Driven Cancers - Nasdaq
Silexion Therapeutics Corp SEC 10-K Report - TradingView
Revolutionary Cancer Drug SIL204 Tackles Both Primary Tumors and Metastasis with 80% Success Rate - StockTitan
Silexion Therapeutics reaches deal to retire convertible note - Investing.com
Silexion Therapeutics Receives Buy Rating from Naz Rahman Following Promising SIL-204 Pre-Clinical Results - TipRanks
Silexion Therapeutics (NASDAQ: SLXN) Announces Path-Breaking Data for SIL204: Stock Soars 30% - DRP Journal
Silexion Therapeutics Reports Positive Data From SIL204 In Pancreatic Cancer Models - Nasdaq
Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer - Benzinga
Silexion Therapeutics Reports Positive Data for SIL204 - TipRanks
Silexion reports initial data from systemic administration of SIL204 - TipRanks
Silexion Therapeutics Reports Positive Efficacy Data for SIL204 in Orthotopic Pancreatic Cancer Models - Nasdaq
Silexion Therapeutics (SLXN) Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models - StreetInsider.com
Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models - GlobeNewswire
Can Silexion's New Pancreatic Cancer Drug Stop Metastasis? Early Data Shows 80% Tumor Reduction - StockTitan
Can Silexion's RNAi Therapy Revolutionize Pancreatic Cancer Treatment? March Data Will Tell - StockTitan
Is Now The Time To Buy Silexion Therapeutics Corp (NASDAQ: SLXN) Stock? - Stocks Register
Silexion completes study of SIL-204 in orthotopic pancreatic cancer models - BioWorld Online
Silexion completes initial study of SIL-204 in pancreatic cancer models - TipRanks
Silexion Therapeutics Completes Initial Study of SIL-204 in Orthotopic Pancreatic Cancer Models - Nasdaq
Silexion Therapeutics Announces Completion of Initial Study - GlobeNewswire
Can Silexion's RNA Therapy Change Pancreatic Cancer Treatment? Key Study Completed - StockTitan
Comparing Silexion Therapeutics (NASDAQ:SLXN) and Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
0.47%
2.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):